• LAST PRICE
    2.9600
  • TODAY'S CHANGE (%)
    Trending Down-0.2100 (-6.6246%)
  • Bid / Lots
    2.7000/ 3
  • Ask / Lots
    3.2300/ 19
  • Open / Previous Close
    3.0525 / 3.1700
  • Day Range
    Low 2.8900
    High 3.1900
  • 52 Week Range
    Low 1.9500
    High 4.5329
  • Volume
    18,348
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 3.17
TimeVolumeLSTA
09:39 ET10003.0525
10:14 ET1003.19
11:51 ET5002.89
12:03 ET4602.965
12:14 ET1002.93
12:38 ET6003.16
01:17 ET11003.1
01:33 ET1672.9108
02:13 ET5002.95
02:15 ET5003
02:26 ET4002.9678
02:45 ET16002.96
03:25 ET85002.9593
03:59 ET2042.96
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesLSTA
Lisata Therapeutics Inc
26.3M
-1.2x
---
United StatesNNVC
NanoViricides Inc
26.3M
-2.7x
---
United StatesENLV
Enlivex Therapeutics Ltd
25.8M
-0.9x
---
United StatesJAN
Janone Inc
27.6M
-0.9x
---
United StatesBIVI
BioVie Inc
28.1M
-0.5x
---
United StatesUBX
UNITY Biotechnology Inc
24.5M
-0.6x
---
As of 2024-05-24

Company Information

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 also has the potential to modify the tumor microenvironment (TME). It is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors. Its CD34+ is a cell therapy technology was targeting an array of diseases, among them, critical limb ischemia, coronary microvascular dysfunction, and diabetic kidney disease.

Contact Information

Headquarters
110 Allen Road, Second FloorBASKING RIDGE, NJ, United States 07920
Phone
908-229-2590
Fax
845-818-3588

Executives

Independent Chairman of the Board
Gregory Brown
Chief Executive Officer, Director
David Mazzo
Executive Vice President - Research & Development, Chief Medical Officer
Kristen Buck
Senior Vice President - Finance and Treasury, Chief Accounting Officer
James Nisco
Independent Director
Mohammad Azab

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$26.3M
Revenue (TTM)
$0.00
Shares Outstanding
8.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.15
EPS
$-2.46
Book Value
$5.91
P/E Ratio
-1.2x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.